In vivo, RFX5 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner

Immunology

Volumn 111, Issue 1, 2004, Pages 53-65

  Rousseau, Philippe ^a   Masternak, Krzysztof ^b   Krawczyk, Michal ^b   Reith, Walter ^b   Dausset, Jean ^c   Carosella, Edgardo D ^a   Moreau, Philippe ^a  

^a Inst Univ d'Hématologie   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Fondation Jean Dausset   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RFX 5; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL LINE; CELL SURFACE; CELL TYPE; CHROMATIN; COMPARATIVE STUDY; CONTROLLED STUDY; GENETIC CONSERVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IMMUNOREGULATION; PRIORITY JOURNAL; PROMOTER REGION; STEADY STATE;

B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FIBROBLASTS; FLOW CYTOMETRY; GENES, MHC CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOBLOTTING; NUCLEAR PROTEINS; PRECIPITIN TESTS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS;

EID: 0346496125     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01783.x     Document Type: Article

References (71)

1. Braud VM, Allan DS, McMichael AJ. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 1999; 11:100-8.
2. Carosella ED, Paul P, Moreau P, Rouas-Freiss N. HLA-G and HLA-E: fundamental and pathophysiological aspects. Immunol Today 2000; 21:532-4.
3. Forte P, Pazmany L, Matter-Reissmann UB, Stussi G, Schneider MK, Seebach JD. HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J Immunol 2001; 167:6002-8.
4. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol 2001; 22:553-5.
5. Lepin EJ, Bastin JM, Allan DS et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30:3552-61.
6. Wei XH, Orr HT. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 1990; 29:131-42.
7. Ulbrecht M, Honka T, Person S, Johnson JP, Weiss EH. The HLA-E gene encodes two differentially regulated transcripts and a cell surface protein. J Immunol 1992; 149:2945-53.
8. Gustafson KS, Ginder GD. Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element. J Biol Chem 1996; 271:20035-46.
9. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998; 160:4951-60.
10. Llano M, Lee N, Navarro F, GarciaP, Albar JP, Geraghty DE, Lopez-Botet M. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998; 28:2854-63.
11. Wainwright SD, Biro PA, Holmes CH. HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol 2000; 164:319-28.
12. McMaster MT, Librach CL, Zhou Y et al Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 1995; 154:3771-8.
13. Houlihan JM, Biro PA, Harper HM, Jenkinson HJ, Holmes CH. The human amnion is a site of MHC class Ib expression: evidence for the expression of HLA-E and HLA-G. J Immunol 1995; 154:5665-74.
14. Hammer A, Hutter H, Blaschitz A, Mahnen W, Hartmann M, Uchanska-Ziegler B, Ziegler A, Dohr G. Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G. Am J Reprod Immunol 1997; 37:161-71.
15. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997; 186:289-98.
16. Blaschitz A, Lenfant F, Mallet V, Hartmann M, Bensussan A, Geraghty DE, Le Bouteiller P, Dohr G. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol 1997; 27:3380-8.
17. Paul P, Cabestre FA, Le Gal FA et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999; 59:1954-60.
18. Urosevic M, Kurrer MO, Kamarashev J et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159:817-24.
19. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001; 61:6838-45.
20. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002; 99:609-17.
21. Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000; 356:220-1.
22. Aractingi S, Briand N, Le Danff C, Viguier M, Bachelez H, Michel L, Dubertret L, Carosella ED. HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol 2001; 159:71-7.
23. Khosrotehrani K, Le Danff C, Reynaud-Mendel B, Dubertret L, Carosella ED, Aractingi S. HLA-G expression in atopic dermatitis. J Invest Dermatol 2001; 117:750-2.
24. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999; 11:803-11.
25. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, Schall TJ. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 2002; 76:1285-92.
26. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J Immunol 1996; 156:4224-31.
27. Chu W, Yang Y, Geraghty DE, Hunt JS. Interferons enhance HLA-G mRNA and protein in transfected mouse fibroblasts. J Reprod Immunol 1999; 42:1-15.
28. Chu W, Fant ME, Geraghty DE, Hunt JS. Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-gamma-activated macrophages but not placental fibroblasts. Hum Immunol 1998; 59:435-42.
29. Lefebvre S, Berrih-Aknin S, Adrian F et al. A specific Interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem 2001; 276: 6133-9.
30. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 2000; 61:1102-7.
31. van den Elsen PJ, Gobin SJ, van Eggermond MC, Peijnenburg A. Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 1998; 48:208-21.
32. Waldburger JM, Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Landmann S, Reith W. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev 2000; 178:148-65.
33. Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Reith W. Molecular genetics of the Bare lymphocyte syndrome. Rev Immunogenet 2000; 2:267-82.
34. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, Reith W. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995; 9:1021-32.
35. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, Reith W. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997; 16:1045-55.
36. Masternak K, Barras E, Zufferey M et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998; 20:273-7.
37. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 1999; 10:153-62.
38. Hasegawa SL, Boss JM. Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters. Nucleic Acids Res 1991; 19:6269-76.
39. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 1999; 10:143-51.
40. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999; 239:15-27.
41. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75:135-46.
42. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265:106-9.
43. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med 1994; 180:1367-74.
44. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 2000; 14:1156-66.
45. Gobin SJ, Peijnenburg A, van Eggermond M, van Zutphen M, van den Berg R, van den Elsen PJ. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes. Immunity 1998; 9:531-41.
46. Gobin SJ, van Zutphen M, Westerheide SD, Boss JM, van den Elsen PJ. The MHC-specific enhanceosome and its role in MHC class I and beta (2) -microglobulin gene transactivation. J Immunol 2001; 167:5175-84.
47. van den Elsen PJ, Peijnenburg A, van Eggermond MC, Gobin SJ. Shared regulatory elements in the promoters of MHC class I and class II genes. Immunol Today 1998; 19:308-12.
48. Gobin SJ, Keijsers V, van Zutphen M, van den Elsen PJ. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J Immunol 1998; 161:2276-83.
49. Gobin SJ, van Zutphen M, Woltman AM, van den Elsen PJ. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol 1999; 163:1428-34.
50. Rousseau P, Paul P, O'Brien M, Dausset J, Carosella ED, Moreau P. The X1 box of HLA-G promoter is a target site for RFX and Sp1 factors. Hum Immunol 2000; 61:1132-7.
51. Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 1966; 37: 547-59.
52. Shimizu Y, Geraghty DE, Koller BH, Orr HT, DeMars R. Transfer and expression of three cloned human non-HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc Natl Acad Sci USA 1988; 85:227-31.
53. Paul P, Rouas-Freiss N, Moreau P et al. HLA-G-E-F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol 2000; 61: 1177-95.
54. Menier C, Saez B, Horejsi V et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 2003; 64:315-26.
55. Masternak K, Peyraud N, Krawczyk M. Barras E, Reith W. Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nat Immunol 2003; 4:132-7.
56. King A, Boocock C, Sharkey AM, Gardner L, Beretta A, Siccardi AG, Loke YW. Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. J Immunol 1996; 156:2068-76.
57. Blaschitz A, Hutter H, Leitner V, Pilz S, Wintersteiger R, Dohr G, Sedlmayr P. Reaction patterns of monoclonal antibodies to HLA-G in human tissues and on cell lines: a comparative study. Hum Immunol 2000; 61:1074-85.
58. Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J Immunol 1989; 142:3320-8.
59. Chumbley G, King A, Robertson K, Holmes N, Loke YW. Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. Cell Immunol 1994; 155:312-22.
60. Boucraut J, Guillaudeux T, Alizadeh M et al. HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR. Immunogenetics 1993; 38:117-30.
61. Celada A, McKercher S, Maki RA. Repression of major histocompatibility complex IA expression by glucocorticoids: the glucocorticoid receptor inhibits the DNA binding of the X box DNA binding protein. J Exp Med 1993; 177:691-8.
62. Murphy SP, Tomasi TB. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression. Mol Reprod Dev 1998; 51: 1-12.
63. van den Elsen PJ, van der Stoep N, Victor HE, Wilson L, van Zutphen M, Gobin SJ. Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-gamma inducible promoter (PIV) of CIITA. Hum Immunol 2000; 61:850-62.
64. Morris AC, Spangler WE, Boss JM. Methylation of class II transactivator promoter IV: a novel mechanism of MHC class II gene control. J Immunol 2000; 164:4143-9.
65. van den Eisen PJ, Gobin SJ, van der Stoep N, Datema G, Vietor HE. Transcriptional control of MHC genes in fetal trophoblast cells. J Reprod Immunol 2001; 52:129-45.
66. Courey AJ, Jia S. Transcriptional repression: the long and the short of it. Genes Dev 2001; 15:2786-96.
67. Solier C, Mallet V, Lenfant F, Bertrand A, Huchenq A, Le Bouteiller P. HLA-G unique promoter region: functional implications. Immunogenetics 2001; 53:617-25.
68. Schmidt CM, Ehlenfeldt RG, Athanasiou MC, Duvick LA, Heinrichs H, David CS, Orr HT. Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice: evidence for a positive regulatory region located 1 kilobase 5′-to the start site of transcription. J Immunol 1993; 151:2633-45.
69. Moreau P, Paul P, Gourand L, Prost S, Dausset J, Carosella E, Kirszenbaum M. HLA-G gene transcriptional regulation in trophoblasts and blood cells: differential binding of nuclear factors to a regulatory element located 1.1 kb from exon 1. Hum Immunol 1997; 52:41-6.
70. Gobin SJ, Biesta P, De Steenwinkel JE, Datema G, Van Den Elsen PJ. HLA-G transactivation by cAMP-response element-binding protein (CREB): an alternative transactivation pathway to the conserved major histocompatibility complex class I regulatory routes. J Biol Chem 2002; 277:39525-31.
71. Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 2003; 100:1191-96.